C/EBP-beta Antibodies

Target Information

an important bZIP transcription factor that regulates the expression of genes involved in immune and inflammatory responses. Plays also a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant functions with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Plays also a role in intracellular bacteria killing. During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation. Essential for female reproduction because of a critical role in ovarian follicle development. Restricts osteoclastogenesis: together with NFE2L1; represses expression of DSPP during odontoblast differentiation. Isoform 2: Essential for gene expression induction in activated macrophages. Plays a major role in immune responses such as CD4(+) T-cell response, granuloma formation and endotoxin shock. Not essential for intracellular bacteria killing. Isoform 3: Acts as a dominant negative through heterodimerization with isoform 2. Promotes osteoblast differentiation and osteoclastogenesis. Belongs to the bZIP family. C/EBP subfamily. Expressed at low levels in the lung, kidney and spleen. 3 alternative initiation human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

C/EBP beta; C/EBP-beta; C/EBP-related protein 2; CCAAT enhancer binding protein beta; CCAAT/enhancer binding protein (C/EBP), beta; CCAAT/enhancer-binding protein beta; CEBPB; Cebpb; CRP2; Crp2; IL-6DBP; IL6DBP; Il6dbp; interleukin 6-dependent DNA-binding protein; Interleukin-6-dependent-binding protein; LAP; LIP; Liver activating protein (LAP also NF-IL6 nuclear factor-IL6 previously designated TCF5); Liver activating protein (LAP, also NF-IL6, nuclear factor-IL6, previously designated TCF5); liver activating protein (LAP); Liver activator protein; Liver-enriched inhibitory protein; Liver-enriched transcriptional activator; liver-enriched transcriptional activator protein; MGC32080; NF-IL6; Nuclear factor NF-IL6; nuclear factor of interleukin 6; nuclear factor-IL6; SF-B; Sfb; Silencer factor B; TCF-5; TCF5; Transcription factor 5; transcription factor C/EBP beta